Javelin Energy Releases Second Quarter 2008 Financial Results -
Javelin Pharmaceuticals to reduce workforce by 15% -
Equedia: Analyst Ratings and Insider Trades for Javelin Pharmaceuticals, Inc. -
BRIEF-Javelin reduces workforce by 15 pct -
Javelin Pharmaceuticals Announces 15 Percent Reduction in Workforce -
BRIEF-Javelin Pharmaceuticals Q3 results -
Javelin Pharmaceuticals, Inc. Reports Third Quarter 2008 Results and Corporate Highlights -
JAV: Q3 Earnings Call @ 08:30 ET Today [delayed] -
Javelin Pharmaceuticals to Review Third Quarter 2008 Financial Results -
Javelin initiates enrollment for Phase III pain trial -
JAV: To Present At UBS Global Life Sciences Conference @ 12:00 ET [delayed] -
JAV: Enrollment Begins for Ph 3 Trial of Dyloject(TM) -
Javelin Enrolls First Patient in an Open Label Safety Study of Dyloject(TM) -
Javelin completes enrollment for second Phase III study of pain drug -
Javelin Pharmaceuticals to Present at the 2008 UBS Global Life Sciences Conference -
JAV: Completes Enrollment in Second Phase 3 Trial of Dyloject(TM) -
JAV: To Present At BioCentury's Biotech Industry Conference @ 11:30 ET [delayed] -
Javelin Energy Releases First Quarter Financial Results -
Javelin Pharmaceuticals CEO to Provide Corporate Overview at the BioCentury NewsMakers Conference -